ADMS - Adamas Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
27.06
+0.72 (+2.73%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close26.34
Open26.25
Bid25.85 x 1000
Ask27.20 x 1000
Day's Range25.86 - 27.56
52 Week Range13.50 - 44.00
Volume491,901
Avg. Volume629,931
Market Cap730.141M
Beta2.19
PE Ratio (TTM)N/A
EPS (TTM)-4.62
Earnings DateNov 1, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.00
Trade prices are not sourced from all markets
  • GlobeNewswire6 days ago

    Adamas Announces New Employment Inducement Grant

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 29,531 shares of the company’s common stock, at a per share exercise price of $25.74, the closing trading price on July 9, 2018, and restricted stock units to acquire 4,921 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

  • ACCESSWIRE20 days ago

    Free Technical Research on Akorn and Three More Generic Drugs Equities

    WallStEquities.com has selected the following Generic Drugs stocks for review today: Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), and Allergan PLC (NYSE: AGN). Companies in the generic pharmaceuticals sector make drugs that are offered cheaper than name-brand pharmaceuticals once patents for the more expensive drugs lapse.

  • GlobeNewswire23 days ago

    Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day

    Adamas Pharmaceuticals, Inc. (ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release capsules, from the Phase 3 pivotal studies, demonstrating that the reductions in both dyskinesia and OFF experienced by GOCOVRI-treated patients results in longer periods of ON time without troublesome dyskinesia and reduced transitions between Parkinson’s disease diary states. The analysis will be presented in an oral poster, entitled ADS-5102 Reduces ON Time with Troublesome Dyskinesia and OFF Time Throughout the Waking Day-Time Course Analysis, at the 2nd Annual Pan American Parkinson’s Diseases and Movement Disorders Congress in Miami, FL. GOCOVRI is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in people with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

  • Why Axovant Sciences Stock Rose in Week Ended June 8
    Market Realistlast month

    Why Axovant Sciences Stock Rose in Week Ended June 8

    Axovant Sciences (AXON) stock rose 150% in the week of June 1–8. Over the last quarter, Axovant Sciences stock has risen 192.7%. On June 6, Axovant Sciences entered into a licensing agreement for worldwide rights to develop and sell Oxford BioMedica’s OXB-102 investigational gene therapy for the treatment of Parkinson’s disease.

  • GlobeNewswirelast month

    Adamas Announces New Employment Inducement Grant

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 37,875 shares of the company’s common stock, at a per share exercise price of $27.68, the closing trading price on June 7, 2018, and restricted stock units to acquire 6,309 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

  • GlobeNewswire2 months ago

    Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics

    EMERYVILLE, Calif., May 24, 2018-- Adamas Pharmaceuticals, Inc. today announced that pharmacokinetic data regarding GOCOVRI™ extended release capsules were published online in Clinical Pharmacokinetics. ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ADMS earnings conference call or presentation 3-May-18 8:30pm GMT

    Q1 2018 Adamas Pharmaceuticals Inc Earnings Call

  • GlobeNewswire2 months ago

    Adamas Announces New Employment Inducement Grant

    Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 19,622 shares of the company’s common stock, at a per share exercise price of $31.34, the closing trading price on May 7, 2018, and restricted stock units to acquire 3,268 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...

  • Associated Press2 months ago

    Adamas: 1Q Earnings Snapshot

    On a per-share basis, the Emeryville, California-based company said it had a loss of $1.35. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Adamas Reports First Quarter 2018 Financial Results

    GOCOVRI™ extended release capsules product sales hit $2.6 million for the first quarter of commercialization, with 1,608 fulfilled prescriptions. Received positive feedback from the U.S. Food and Drug ...

  • GlobeNewswire2 months ago

    Adamas to Present at Two Upcoming Investor Conferences

    EMERYVILLE, Calif., May 02, 2018-- Adamas Pharmaceuticals, Inc. today announced that company management is scheduled to present at two upcoming investor conferences:. Gregory T. Went, Ph.D., the company’ ...

  • ACCESSWIRE3 months ago

    Blog Exposure - Adamas Pharma Announced Final Results from EASE LID 2 Study Evaluating GOCOVRI in Parkinson’s Disease Patients with Dyskinesia

    LONDON, UK / ACCESSWIRE / April 23, 2018 / Active-Investors.com has just released a free research report on Adamas Pharma, Inc. (NASDAQ: ADMS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ADMS as the Company's latest news hit the wire. On April 18, 2018, the Company announced positive data from the completed Phase-3 open-label trial, EASE LID 2, assessing GOCOVRI™ (amantadine) extended release capsules for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

  • Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?
    Simply Wall St.3 months ago

    Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Earnings Dropped -49.01%, How Did It Fare Against The Industry?

    When Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I usedRead More...

  • GlobeNewswire3 months ago

    Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia

    Adamas Pharmaceuticals, Inc. (ADMS) today announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Overall, results demonstrated that GOCOVRI was generally well tolerated and the treatment effect on motor complications (dyskinesia and OFF), as measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Part IV, was maintained for up to two years.

  • Benzinga4 months ago

    Gocovri Stabilizes Adamas Stock, Secures Another Buy Rating

    Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) shares have been sensitive to recent news around Gocovri, the firm’s leading pipeline candidate. The drug is a proven gateway to the stock and lured an industry ...

  • Acorda Files Parkinson's Drug Marketing Application in EU
    Zacks4 months ago

    Acorda Files Parkinson's Drug Marketing Application in EU

    Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of ADMS earnings conference call or presentation 22-Feb-18 9:30pm GMT

    Q4 2017 Adamas Pharmaceuticals Inc Earnings Call

  • What Should Investors Know About Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Future?
    Simply Wall St.4 months ago

    What Should Investors Know About Adamas Pharmaceuticals Inc’s (NASDAQ:ADMS) Future?

    In December 2017, Adamas Pharmaceuticals Inc (NASDAQ:ADMS) announced its latest earnings update, which revealed that losses became smaller relative to the prrior year’s level – great news for investors Below,Read More...